Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGNNASDAQ:APMNASDAQ:CINGNYSE:TMBR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGNApexigen$0.39$0.39$0.33▼$8.28$9.57M3.6967,731 shsN/AAPMAptorum Group$1.04-4.6%$0.96$0.46▼$7.49$5.56M-0.14619,192 shs18,267 shsCINGCingulate$4.45$4.12$1.80▼$20.83$18.89M-0.851.10 million shs147,636 shsTMBRTimber Pharmaceuticals$1.87$0.32▼$3.39$1.21M0.03511,937 shs26,307 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGNApexigen0.00%0.00%0.00%0.00%0.00%APMAptorum Group0.00%-11.86%+14.79%+13.04%-76.89%CINGCingulate0.00%+1.14%+22.93%+12.37%+680.70%TMBRTimber Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPGNApexigenN/AN/AN/AN/AN/AN/AN/AN/AAPMAptorum Group0.4761 of 5 stars0.03.00.00.00.61.70.6CINGCingulate2.1566 of 5 stars3.52.00.00.02.50.80.6TMBRTimber PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGNApexigen 0.00N/AN/AN/AAPMAptorum Group 0.00N/AN/AN/ACINGCingulate 3.00Buy$26.00484.27% UpsideTMBRTimber Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CING, APGN, APM, and TMBR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$60.00 ➝ $61.005/19/2025CINGCingulateRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$12.00 ➝ $11.004/21/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $60.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGNApexigenN/AN/AN/AN/A($0.09) per shareN/AAPMAptorum Group$430K12.94N/AN/A$2.20 per share0.47CINGCingulateN/AN/AN/AN/A$2.32 per shareN/ATMBRTimber Pharmaceuticals$80K0.00N/AN/A$1.79 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGNApexigen-$32.07MN/A0.00∞N/AN/A-614.82%-133.30%N/AAPMAptorum Group-$4.27MN/A0.00∞N/AN/AN/AN/A7/30/2025 (Estimated)CINGCingulate-$15.55M-$8.48N/AN/AN/AN/A-229.78%-142.28%8/12/2025 (Estimated)TMBRTimber Pharmaceuticals-$19.38MN/A0.00N/AN/AN/A-511.45%-180.93%N/ALatest CING, APGN, APM, and TMBR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CINGCingulate-$1.00-$1.04-$0.04-$1.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPGNApexigenN/AN/AN/AN/AN/AAPMAptorum GroupN/AN/AN/AN/AN/ACINGCingulateN/AN/AN/AN/AN/ATMBRTimber PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGNApexigenN/A0.820.82APMAptorum GroupN/A0.220.22CINGCingulate0.161.871.87TMBRTimber PharmaceuticalsN/A0.500.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGNApexigen13.65%APMAptorum Group3.80%CINGCingulate41.31%TMBRTimber Pharmaceuticals3.62%Insider OwnershipCompanyInsider OwnershipAPGNApexigen19.20%APMAptorum Group63.99%CINGCingulate5.27%TMBRTimber Pharmaceuticals1.61%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGNApexigen1124.86 million20.09 millionNot OptionableAPMAptorum Group305.35 million1.93 millionNot OptionableCINGCingulate204.25 million4.02 millionNot OptionableTMBRTimber Pharmaceuticals93.43 million3.38 millionNot OptionableCING, APGN, APM, and TMBR HeadlinesRecent News About These CompaniesMSG Networks in talks to avoid bankruptcy — possibly with help of Amazon: sourcesJanuary 31, 2025 | nypost.comTimber back in Dutch squad and twin brother also called upAugust 30, 2024 | reuters.comRare disease drug from LEO's Timber felled by failed studyAugust 25, 2024 | pharmaphorum.comCan timber construction overcome its growing pains?May 13, 2024 | reuters.comTimber Pharmaceuticals, Inc., a LEO Pharma Company, Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis (CI) at the 2024 AAD Annual MeetingMarch 10, 2024 | businesswire.comTimber Pharmaceuticals Announces Official Name ChangeJanuary 28, 2024 | msn.comTimber Pharmaceuticals Inc (TMBRQ)January 13, 2024 | uk.investing.comTimber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC MarketNovember 29, 2023 | finance.yahoo.comNYSE American to Suspend Trading Immediately in Timber Pharmaceuticals, Inc. (TMBR)November 29, 2023 | finance.yahoo.comTimber Pharmaceuticals Receives Court Approval of All "First Day" Motions to Support Business Operations & Discloses Communication From NYSE AmericanNovember 28, 2023 | tmcnet.comTimber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE AmericanNovember 28, 2023 | finance.yahoo.comMVST, FBIO and VTVT among mid-day moversNovember 21, 2023 | seekingalpha.comTimber Pharmaceuticals files for Chapter 11 in wake of failed mergerNovember 17, 2023 | msn.comTimber Pharma slips ahead of shareholder vote on mergerNovember 16, 2023 | msn.comTimber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing ComplianceSeptember 18, 2023 | finance.yahoo.comHC Wainwright Downgrades Timber PharmaceuticalsAugust 29, 2023 | 247wallst.comHC Wainwright & Co. Downgrades Timber Pharmaceuticals (TMBR)August 28, 2023 | msn.comTimber Pharmaceuticals rockets as it agrees to a takeoverAugust 21, 2023 | thepharmaletter.comTMBR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Timber Pharmaceuticals, Inc. Is Fair to ShareholdersAugust 21, 2023 | benzinga.comDow Tumbles Over 100 Points; Timber Pharmaceuticals Shares Spike HigherAugust 21, 2023 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher's Midnight Air Taxi Soars, But Stock Doesn’t BudgeBy Jeffrey Neal Johnson | June 4, 2025View Archer's Midnight Air Taxi Soars, But Stock Doesn’t BudgeHims & Hers Stock: Buy the Dip or Wait It Out?By Gabriel Osorio-Mazilli | June 5, 2025View Hims & Hers Stock: Buy the Dip or Wait It Out?Intel's Dual Gamble: AI Innovation Now, Foundry Fortunes Later?By Jeffrey Neal Johnson | June 8, 2025View Intel's Dual Gamble: AI Innovation Now, Foundry Fortunes Later?Is Lululemon’s 18% Selloff Overdone? Analysts Say YesBy Gabriel Osorio-Mazilli | June 9, 2025View Is Lululemon’s 18% Selloff Overdone? Analysts Say YesAppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target AnywayBy Leo Miller | June 10, 2025View AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target AnywayCING, APGN, APM, and TMBR Company DescriptionsApexigen NASDAQ:APGNApexigen, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. Apexigen, Inc. was founded in 2010 and is headquartered in San Carlos, California.Aptorum Group NASDAQ:APM$1.04 -0.05 (-4.59%) Closing price 06/18/2025 03:58 PM EasternExtended Trading$1.06 +0.02 (+2.31%) As of 06/18/2025 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.Cingulate NASDAQ:CING$4.45 0.00 (0.00%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$4.60 +0.15 (+3.26%) As of 06/18/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Timber Pharmaceuticals NYSE:TMBRTimber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
